| Attribute |
Value |
| 52 Week Change |
0.41213393 |
| Address1 |
30 Hudson Street |
| Address2 |
Floor 33 |
| All Time High |
39.475 |
| All Time Low |
5.69 |
| Ask |
13.51 |
| Ask Size |
1,700 |
| Audit Risk |
10 |
| Average Daily Volume10 Day |
2,437,180 |
| Average Daily Volume3 Month |
7,487,629 |
| Average Volume |
7,487,629 |
| Average Volume10Days |
2,437,180 |
| Beta |
1.536 |
| Bid |
13.5 |
| Bid Size |
2,000 |
| Board Risk |
2 |
| Book Value |
3.438 |
| City |
Jersey City |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
1 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
13.5 |
| Current Ratio |
1.973 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
13.51 |
| Day Low |
13.5 |
| Debt To Equity |
948.948 |
| Display Name |
Organon & |
| Dividend Date |
1,781,136,000 |
| Dividend Rate |
0.08 |
| Dividend Yield |
0.59 |
| Earnings Call Timestamp End |
1,778,157,000 |
| Earnings Call Timestamp Start |
1,778,157,000 |
| Earnings Growth |
0.667 |
| Earnings Quarterly Growth |
0.678 |
| Earnings Timestamp |
1,777,552,200 |
| Earnings Timestamp End |
1,777,552,200 |
| Earnings Timestamp Start |
1,777,552,200 |
| Ebitda |
1,595,000,064 |
| Ebitda Margins |
0.2588 |
| Enterprise To Ebitda |
6.895 |
| Enterprise To Revenue |
1.785 |
| Enterprise Value |
10,998,111,232 |
| Eps Current Year |
3.621 |
| Eps Forward |
3.63838 |
| Eps Trailing Twelve Months |
0.93 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,778,457,600 |
| Exchange |
NYQ |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
13.4158 |
| Fifty Day Average Change |
0.084199905 |
| Fifty Day Average Change Percent |
0.006276175 |
| Fifty Two Week Change Percent |
41.213394 |
| Fifty Two Week High |
13.6 |
| Fifty Two Week High Change |
-0.10000038 |
| Fifty Two Week High Change Percent |
-0.007352969 |
| Fifty Two Week Low |
5.69 |
| Fifty Two Week Low Change |
7.81 |
| Fifty Two Week Low Change Percent |
1.3725835 |
| Fifty Two Week Range |
5.69 - 13.6 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,620,999,000,000 |
| Float Shares |
261,077,777 |
| Forward Eps |
3.63838 |
| Forward P E |
3.7104425 |
| Free Cashflow |
529,124,992 |
| Full Exchange Name |
NYSE |
| Full Time Employees |
10,000 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,782,864,000 |
| Gross Margins |
0.53837 |
| Gross Profits |
3,318,000,128 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.00466 |
| Held Percent Institutions |
0.78093004 |
| Implied Shares Outstanding |
262,609,433 |
| Industry |
Drug Manufacturers - General |
| Industry Disp |
Drug Manufacturers - General |
| Industry Key |
drug-manufacturers-general |
| Is Earnings Date Estimate |
0 |
| Language |
en-US |
| Last Dividend Date |
1,778,457,600 |
| Last Dividend Value |
0.02 |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey. |
| Long Name |
Organon & Co. |
| Market |
us_market |
| Market Cap |
3,545,227,520 |
| Market State |
REGULAR |
| Max Age |
86,400 |
| Message Board Id |
finmb_653748561 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
246,000,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
3,545,227,345 |
| Number Of Analyst Opinions |
4 |
| Open |
13.5 |
| Operating Cashflow |
850,000,000 |
| Operating Margins |
0.18699 |
| Overall Risk |
3 |
| Payout Ratio |
0.086 |
| Phone |
551 430 6900 |
| Previous Close |
13.505 |
| Price Eps Current Year |
3.7282517 |
| Price Hint |
2 |
| Price To Book |
3.9267015 |
| Price To Sales Trailing12 Months |
0.57524383 |
| Profit Margins |
0.039920002 |
| Quick Ratio |
1.0 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
-0.0050001144 |
| Regular Market Change Percent |
-0.03702417 |
| Regular Market Day High |
13.51 |
| Regular Market Day Low |
13.5 |
| Regular Market Day Range |
13.5 - 13.51 |
| Regular Market Open |
13.5 |
| Regular Market Previous Close |
13.505 |
| Regular Market Price |
13.5 |
| Regular Market Time |
1,784,036,829 |
| Regular Market Volume |
55,806 |
| Return On Assets |
0.05889 |
| Return On Equity |
0.34048 |
| Revenue Growth |
-0.035 |
| Revenue Per Share |
23.693 |
| Sand P52 Week Change |
0.20365608 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
1 |
| Shares Outstanding |
262,609,433 |
| Shares Percent Shares Out |
0.0651 |
| Shares Short |
17,087,338 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
18,074,491 |
| Short Name |
Organon & Co. |
| Short Percent Of Float |
0.074 |
| Short Ratio |
7.0 |
| Source Interval |
15 |
| State |
NJ |
| Symbol |
OGN |
| Target High Price |
14.0 |
| Target Low Price |
8.0 |
| Target Mean Price |
11.25 |
| Target Median Price |
11.5 |
| Total Cash |
1,116,000,000 |
| Total Cash Per Share |
4.25 |
| Total Debt |
8,568,999,936 |
| Total Revenue |
6,162,999,808 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.08 |
| Trailing Annual Dividend Yield |
0.0059237317 |
| Trailing Eps |
0.93 |
| Trailing P E |
14.516129 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
9.3296 |
| Two Hundred Day Average Change |
4.1703997 |
| Two Hundred Day Average Change Percent |
0.44700733 |
| Type Disp |
Equity |
| Volume |
55,806 |
| Website |
https://www.organon.com |
| Zip |
7,302 |